Peer-reviewed evidence,
curated for context.
Selected publications across the conditions we care for. Curated from PubMed and major medical journals. Educational, not medical advice.
- Stem Cells and Development·2020
Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19
Sengupta et al.24 patients with severe COVID-19 ARDS received a single IV dose of bone marrow MSC-derived exosomes (ExoFlo). 83% survival rate, significant reduction in inflammatory markers (CRP, ferritin, D-dimer), and improvement in oxygenation within 72 hours.
- Stem Cell Research & Therapy·2022·NCT04276987 (MEXCOVID)
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19
Zhu et al.7 patients with severe COVID-19 pneumonia received 5 consecutive daily nebulized doses of haMSC-Exos. Well tolerated, no adverse events, with CT imaging improvement of pulmonary lesions in 4 of 7 patients within 7 days.
- Stem Cell Reviews and Reports·2022·ChiCTR2000030261
Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia
Chu et al.Nebulized UCMSC-derived exosomes were safe (no acute or secondary allergic reactions), promoted pulmonary lesion absorption, and reduced hospitalization duration in mild COVID-19 cases. Authors recommend earliest-possible administration for maximum benefit.
- CHEST·2023
Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial
Lightner et al.Phase II randomized placebo-controlled trial of two IV doses of BM-MSC EVs in COVID-19 respiratory failure. Demonstrated feasibility of large-scale clinical-grade MSC-EV production and excellent clinical tolerance.
Articles curated for educational context only and do not constitute medical advice. For clinical questions, message your physician through the patient portal or contact our team.
The 351(a) medical pathway for biologic drugs.
Section 351 of the Public Health Service Act governs the licensing of biological products in the United States. Two distinct regulatory routes exist: 351(a), which requires full FDA pre-market review and approval, and 361, which permits minimally manipulated, homologous-use tissue products without pre-market approval.
What 351(a) requires
Investigational biologic drugs delivered under 351(a) require an Investigational New Drug (IND) application reviewed by the FDA, an Institutional Review Board (IRB) approval of the clinical protocol, and explicit informed consent from every enrolled patient. Manufacturing must follow Current Good Manufacturing Practice (cGMP) standards. Outcomes are reported back to the FDA and the broader scientific community.
What 361 does not cover
361-regulated products are limited to minimal manipulation and homologous use of the patient's own tissue. Expanded MSC populations, exosome isolates, and allogeneic cellular products generally fall outside 361 and require the 351(a) framework.
Why this matters for patients
Clinical research programs that operate under 351(a) carry substantially more regulatory oversight than wellness-clinic offerings that lean on 361 framing for products that arguably don't qualify. Knowing which pathway a product follows is one of the most important questions to ask any clinic offering cellular therapy.
How RegenBio Care operates
RegenBio Care's structured clinical research programs operate within the 351(a) framework. Investigational products are delivered under appropriate IND/IDE coverage, with IRB-approved informed consent before any patient enrolls. Standard regenerative-medicine services delivered through the physician network follow each physician's licensure and standard of care.
This primer is an introduction. For deeper questions on regulatory classification or how it applies to your case, ask your physician during your consultation.
Want to dig deeper?
Browse the full Regenerative Research catalogue with category filters and a Sherlock-backed Google Scholar search.